Gene Therapy Follow-Up: Balance Data Needs And Patient Burden, Bluebird Bio Exec Says

The FDA often requires 15 years of postmarket follow-up for approved gene therapies. (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Cell & Gene Therapies

More from R&D